Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    625 result(s) found for: Retinal. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000800-13 Sponsor Protocol Number: V1 Start Date*: 2013-01-24
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Influence of sustained-release dexamethasone on intraocular cytokines and growth factors and retinal blood vessels in retinal vein occlusion
    Medical condition: Retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10066426 Hemiretinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002790-11 Sponsor Protocol Number: V4.0 Start Date*: 2015-06-08
    Sponsor Name:Ludwig-Maximilians Universität München
    Full Title: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004656-38 Sponsor Protocol Number: CRF002EVA Start Date*: 2015-03-11
    Sponsor Name:Prof. Dr. Karl-Heinz Emmerich
    Full Title: Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema caused by retinal or central retinal vein occlusion under therapy with Lucentis® (ranibizumab)
    Medical condition: Central retinal vein occlusion Retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017782-30 Sponsor Protocol Number: Lucentis in CRVO Start Date*: 2010-03-22
    Sponsor Name:Medizinische Universität Graz, Universitäts-Augenklinik
    Full Title: Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®).
    Medical condition: This case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007972 Central retinal vein occlusion LLT
    12.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001678-25 Sponsor Protocol Number: 138/06 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.
    Medical condition: vascular retinopathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038923 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020441-27 Sponsor Protocol Number: CORaLa Start Date*: 2011-02-23
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of ...
    Medical condition: macular edema secondary to non-ischemic central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10054467 Macular edema LLT
    14.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005473-20 Sponsor Protocol Number: V121102015 Start Date*: 2016-11-23
    Sponsor Name:UZ Leuven
    Full Title: Pilot study on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion.
    Medical condition: Patients with central retinal vein occlusion (CRVO)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011403-23 Sponsor Protocol Number: CHIC2009-01 Start Date*: 2009-08-10
    Sponsor Name:Centre Hospitalier Intercommunal de Créteil
    Full Title: ETUDE PILOTE SUR L’EFFICACITE ET LA TOLERANCE DES INJECTIONS INTRA-VITREENNES DE LUCENTIS (RANIBIZUMABÒ) A LA PHASE INITIALE DES OCCLUSIONS DE LA VEINE CENTRALE DE LA RETINE
    Medical condition: Central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000742-35 Sponsor Protocol Number: RTBAIEOP018 Start Date*: 2021-05-05
    Sponsor Name:ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: PROTOCOL FOR THE DIAGNOSIS AND THERAPY OF INTRAOCULAR RETINOBLASTOMA
    Medical condition: Intraocular retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014444-11 Sponsor Protocol Number: RET04.09 Start Date*: 2009-08-10
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038901 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003374-24 Sponsor Protocol Number: OP-2005-01 Start Date*: 2005-09-12
    Sponsor Name:OPOCRIN S.P.A.
    Full Title: A phase 2, controlled, multi-center pilot study to evaluate the efficacy and safety of Deligoparin in subjects with retinal vein occlusion of recent onset.
    Medical condition: Treatment of retinal vein occlusion.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038907 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001727-19 Sponsor Protocol Number: 45/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Triamcinolone Acetonide Intravitreal Injection for the treatment for exudative maculopathy
    Medical condition: exudative maculopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038862 Retinal exudates LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000681-42 Sponsor Protocol Number: CoRaLa_II Start Date*: 2020-08-24
    Sponsor Name:Justus-Liebig University Gießen
    Full Title: Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion
    Medical condition: Macular edema due to central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005439-10 Sponsor Protocol Number: RabOCT Start Date*: 2013-08-30
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retin...
    Medical condition: macular edema secondary to branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10054467 Macular edema LLT
    18.1 100000004853 10038906 Retinal vein branch occlusion LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001571-37 Sponsor Protocol Number: AAV2/2-hRPE65p-hRPE65 Start Date*: 2006-12-14
    Sponsor Name:University College London
    Full Title: AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION
    Medical condition: The condition to be investigated is severe early-onset inherited retinal degeneration due to defects in the gene encoding RPE65
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10038845 Retinal degeneration PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007175-24 Sponsor Protocol Number: CRFB002AHU02T Start Date*: 2009-02-06
    Sponsor Name:University of Pécs, Medical School, Department of Ophthalmology
    Full Title: A randomized, controlled, two-center phase II. study assessing the efficacy and safety of intravitreal Lucentis injections in patients with clinically significant macular edema secondary to central...
    Medical condition: Macular edema secondary to central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010973-19 Sponsor Protocol Number: 14130 Start Date*: 2009-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondar...
    Medical condition: Maculare edema secondary to Central Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) LV (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000440-63 Sponsor Protocol Number: GR41984 Start Date*: 2020-09-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL ...
    Medical condition: Macular edema secondary to Branch Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PT (Completed) AT (Completed) CZ (Completed) PL (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005789-30 Sponsor Protocol Number: IOBA-03-2008 Start Date*: 2009-04-22
    Sponsor Name:María Isabel López Gálvez-Instituto Universitario de Oftalmobiología Aplicada-Universidad Valladolid
    Full Title: Estudio de la eficacia y seguridad de inyecciones intravítreas de bevacizumab en el edema macular secundario a oclusiones venosas retinianas (EBOVER)
    Medical condition: Edema macular secundario a oclusiones venosas retinianas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030009 Occlusion retinal vein LLT
    9.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000165-20 Sponsor Protocol Number: OZUROFT01/12 Start Date*: 2012-04-13
    Sponsor Name:Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid
    Full Title: SEQUENTIAL CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB AS RESCUE TREATMENT OF RECURRENT MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH OZURDEX
    Medical condition: Macular edema secondary to retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA